Testing version — LOERadar is in active testing. Features and data may change.
KYTRIL (GRANISETRON HYDROCHLORIDE) | LOERadar
KYTRIL
NDA
GRANISETRON HYDROCHLORIDE | N020239 | HOFFMANN LA ROCHE INC
4 strengths0 unique patents0 unique exclusivities
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
Para IV certification filed but no ANDA patent litigation cases (NOS 835) matched from PACER. Litigation may be pending or filed under a different caption.
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (4)
Sort:
#001 — EQ 3MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
RLD
0 patents0 exclusivities▴
INJECTABLE;INJECTION | Approved: Dec 29, 1993
No patent or exclusivity listings for this strength.
#002 — EQ 4MG BASE/4ML (EQ 1MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
RLD
0 patents0 exclusivities▾
INJECTABLE;INJECTION | Approved: Mar 11, 1994
#003 — EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
RLD
0 patents0 exclusivities▾
INJECTABLE;INJECTION | Approved: Sep 17, 2004
#004 — EQ 1MG BASE/ML (EQ 1MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**